Rapid growth in emerging markets, significant new market players and unprecedented levels of M&A are generating both challenges and opportunities for chemicals companies and those investing in the sector.

At Linklaters, we understand and can support our clients in addressing some of the key issues including:
  • fast changing competitive landscape with the recent M&A spike and the break-up of the traditional chemicals conglomerate
  • shift in global sector economics with the supply base moving west and the demand base moving east
  • extraterritorial reach of national laws which have far reaching implications for global businesses

We advise chemicals companies and those investing in the sector on a wide range of corporate, M&A and finance matters and we have a strong regulatory team who are extremely well placed to advise on sector-specific issues such as product and trade regulations.

Through our long history of advising clients in the chemicals sector and our recent roles on three of the four ‘mega-mergers’ we understand how the chemicals sector works and what drives the companies operating and investing in this space. This means that we do not need to spend time getting to grips with the basic issues and are able to provide you with informed, targeted and commercial advice from the outset, saving you time and money.

Recent experience includes advising:
  • Linde Aktiengesellschaft on the three further divestments and the completion of a complex carve-out which finally cleared the path for the business combination of Linde AG and Praxair, Inc
  • Bayer AG on the US$67bn financing aspects of the settlement of its cash only offer for the acquisition of Monsanto
  • Merrill Lynch International on the €6bn discounted rights issue by Bayer to refinance a portion of their acquisition of Monsanto
  • HSBC and other lenders on the debt financing for ChemChina on the US$43bn acquisition of Syngenta
  • Merck KGaA and Merck Financial Services GmbH on their US$6.3bn financing of the proposed acquisition of all shares of common stock in Versum Materials, Inc. by way of a tender offer
  • Bayer on the carve out of its MaterialScience business and on the IPO of the new entity Covestro
  • Solvay on the US$5.5bn merger agreement with U.S. based Cytec and on the subsequent reorganisation of its corporate structure
  • Mitsui on its acquisition, together with Denka, of DuPont’s global neoprene business
  • Sherwin-Williams on the merger filings required in the EU, Russia, Latin-America and Asia-Pacific (except China and Australia) for its acquisition of Valspar for US$11.3bn
  • Alent on the £1.35bn recommended cash offer by Platform Speciality Products Corporation